Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Research Group
Prostate and Urologic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Recruiting ID
For more information, see NCT04300855
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 405 mgs vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate managed on active surveillance
Placebo, Sunphenon
Prostate Cancer, Prostate Adenocarcinoma
Nagi Kumar, PhD, RD, FADA, Kenneth Gage, MD, PhD, Brandon Manley, MD, Jasreman Dhillon, MD, Julio Pow-Sang, MD, Michael Schell, PhD, Michael Poch, MD, Kosj Yamoah, MD, Roger Li, MD, Christine Pierce, PhD, William Parker, MD, Lenora Overton, Jillian Montan, Arnay Marshall

See list of participating sites